Moderna and generation bio announce strategic collaboration to develop non-viral genetic medicines

Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using generation bio's proprietary stealth cell-targeted lipid nanoparticle (ctlnp) delivery system moderna has acquired an option to license generation bio's ctlnp and closed-ended dna (cedna) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program moderna will fund all research and development activities under the collaboration generation bio will receive a $40 million upfront cash payment, a pre-payment of research funding, plus a $36 million equity investment from moderna, with the potential for additional milestones, fees, and royalties cambridge, ma / accesswire / march 23, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and generation bio co. (nasdaq:gbio), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine moderna's biological and technical expertise with core technologies of generation bio's non-viral genetic medicine platform. the collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.
GBIO Ratings Summary
GBIO Quant Ranking